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Background: Hospital-acquired pneumonia (HAP) is defined as radiologically confirmed
pneumonia occurring 48 h after hospitalization, in non-intubated patients. Empirical
treatment regimens use broad-spectrum antimicrobials.
Aim: To evaluate the accuracy of the diagnosis of HAP and to describe the demographic
and microbiological features of patients with HAP.
Methods: Medical and surgical inpatients receiving intravenous antimicrobials for a clin-
ical diagnosis of HAP at a UK tertiary care hospital between April 2013 and 2014 were
identified. Demographic and clinical details were recorded.
Findings: A total of 166 adult patientswith a clinical diagnosis ofHAPwere identified. Broad-
spectrum antimicrobials were prescribed, primarily piperacillinetazobactam (57.2%) and
co-amoxiclav (12.5%). Sputum from 24.7% of patients was obtained for culture. Sixty-five
percent of patients had radiological evidence of new/progressive infiltrate at the time of
HAP treatment, thereforemeetingHAPdiagnostic criteria (2005 AmericanThoracic Society/
Infectious Diseases Society of America guidelines). Radiologically confirmed HAP was asso-
ciated with higher levels of inflammatory markers and sputum culture positivity. Previous
surgery and/or endotracheal intubation were associated with radiologically confirmed HAP.
A bacterial pathogen was identified from 17/35 sputum samples from radiologically
confirmedHAPpatients. ThesewereGram-negativebacilli (N¼11) or Staphylococcus aureus
(N ¼ 6). Gram-negative bacteria tended to be resistant to co-amoxiclav, but susceptible to
ciprofloxacin, piperacillinetazobactam and meropenem. Five of the six S. aureus isolates
were meticillin susceptible and all were susceptible to doxycycline.
Conclusion: In ward-level hospital practice ‘HAP’ is an over-used diagnosis that may be
inaccurate in 35% of cases when objective radiological criteria are applied. Radiologically
confirmed HAP represents a distinct clinical and microbiological phenotype. Potential risk
factors were identified that could represent targets for preventive interventions.
ª 2015 The Authors. Published by Elsevier Ltd
on behalf of the Healthcare Infection Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Infectious Diseases Unit,
Edinburgh EH4 2XU, UK.
@nhslothian.scot.nhs.uk
Elsevier Ltd on behalf of the
ivecommons.org/licenses/by-Introduction
The syndrome of hospital-acquired pneumonia (HAP) is
defined as pneumonia occurring in non-intubated patientsHealthcare Infection Society. This is an open access article
nc-nd/4.0/).
Table I
Patient characteristics
Characteristics All patients Radiologically confirmed HAP Radiology inconsistent with HAP P-valuea
(N ¼ 166) (N ¼ 108) (N ¼ 54)
Male 99 (59.6%) 67 (62.0%) 31 (57.4%) 0.6
Age
Median years (IQR) 79.5 (69e87) 77 (68e86) 81 (71e88)
65 years 138 (83.1%) 88 (81.5%) 46 (85.2%) 0.7
75 years 104 (62.7%) 63 (58.3%) 38 (70.4%) 0.2
Admitted by medicine 125 (75.3%) 75 (69.4%) 46 (85.2%) 0.04
Admitted by surgery 41 (24.7%) 33 (30.6%) 8 (14.8%)
Emergency surgery 24 19 5 1.0
Elective surgery 17 14 3
Nursing home resident 5 (3.0%) 2 (1.9%) 3 (5.6%) 0.3
Medical history
COPD 45 (27.1%) 32 (29.6%) 12 (22.2%) 0.4
Asthma 11 (6.6%) 10 (9.3%) 1 (1.9%) 0.1
Bronchiectasis 4 (2.4%) 3 (2.8%) 1 (1.9%) 1.0
Pulmonary fibrosis 2 (1.2%) 2 (1.9%) 0 0.6
Other lung disease 4 (2.4%) 3 (2.8%) 1 (1.9%) 1.0
IHD 36 (21.7%) 22 (20.4%) 13 (24.1%) 0.7
Heart failure 34 (20.5%) 22 (20.4%) 11 (20.4%) 1.0
Stroke/TIA 43 (25.9%) 26 (24.1%) 17 (31.5%) 0.3
Other neurological disease 10 (6.0%) 7 (6.5%) 2 (3.7%) 0.7
Cognitive impairment 32 (19.3%) 17 (15.7%) 13 (24.1%) 0.2
Chronic liver disease 3 (1.8%) 3 (2.8%) 0 0.6
Chronic kidney disease 15 (9.0%) 6 (5.6%) 9 (16.7%) 0.04
Solid malignancy 23 (13.9%) 11 (10.2%) 11 (20.4%) 0.09
Haematological malignancy 5 (3.0%) 3 (2.8%) 2 (3.7%) 1.0
Type 1 DM 3 (1.8%) 1 (0.9%) 3 (5.6%) 0.1
Type 2 DM 29 (17.5%) 19 (17.6%) 9 (16.7%) 1.0
Immunosuppressive drugs 1 (0.6%) 1 (0.9%) 0 1.0
Dysphagia/GI dysmotility/NG
tube fed (new or old)
33 (19.9%) 25 (23.1%) 8 (14.8%) 0.3
HAP, hospital-acquired pneumonia; IQR, interquartile range; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; TIA,
transient ischaemic attack; DM, diabetes mellitus; GI, gastrointestinal; NG, nasogastric.
a Comparing patients with radiologically confirmed HAP and patients with radiology inconsistent with HAP; chi-square test or Fisher’s exact test
depending on number of subjects.
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time of admission.1 This is distinct from ventilator-associated
pneumonia (VAP), which is defined as pneumonia occurring
after 48e72 h of mechanical ventilation in an intubated pa-
tient. HAP may be suspected if a patient develops new symp-
toms and signs consistent with respiratory tract infection
(fever, abnormal chest examination, purulent sputum,
tachypnoea, impaired oxygenation) and laboratory results
consistent with inflammation (raised white cell count and C-
reactive protein). However, the diagnosis of HAP also requires
radiological demonstration of a new or progressive lung infil-
trate.1 American Thoracic Society/Infectious Diseases Society
of America (ATS/IDSA) guidelines for the management of HAP
highlight Gram-negative bacilli as frequently occurring patho-
gens in HAP and Staphylococcus aureus as an emerging cause.
Much of the literature that has been used to describe the
aetiology of HAP relates to VAP, nosocomial pneumonia
occurring specifically in the intensive care unit (ICU) or nursing-
home-acquired pneumonia.1e6 Overall, more is known aboutthe pathogenesis and microbiology of VAP, facilitated by the
ease of obtaining deep respiratory samples by bronchoalveolar
lavage in intubated patients. Importantly, there are evidence-
based ‘care bundles’ to prevent VAP, but not HAP.7
Empirical treatment of HAP aims to include cover for noso-
comial pathogens, especially Gram negative bacteria, there-
fore it necessitates using broad-spectrum agents such as co-
amoxiclav and piperacillinetazobactam, with the attendant
risks of antibiotic-associated diarrhoea, C. difficile infection,
selection for antimicrobial resistance in patient and environ-
mental flora and also high costs. An accurate diagnosis of HAP is
therefore essential to ensure appropriate use of these
antimicrobials.
The aim of this study was to retrospectively evaluate the
accuracy of the diagnosis of HAP in inpatients on acute internal
medicine and general surgical wards receiving intravenous
antimicrobials for a clinical diagnosis of HAP made by the pa-
tient’s team. The demographic and microbiological features of
patients with radiologically confirmed HAP will be described.
Table II
Admission events, chest X-ray features, antimicrobial treatment, and outcomes
All patients Radiologically confirmed HAP Radiology inconsistent with HAP P-valuea
(N ¼ 166) (N ¼ 108) (N ¼ 54)
Admission events
Surgery pre HAP 39 (23.5%) 33 (30.6%) 6 (11.1%) 0.006
ICU admission pre HAP 29 (17.5%) 23 (21.3%) 6 (11.1%) 0.13
Intubation pre HAPb 45 (27.1%) 36 (33.3%) 8 (14.8%) 0.01
Admission CXR features
Clear lung fields 103 (62.0%) 65 (60.2%) 37 (68.5%) 0.4
Consolidation 15 (9.0%) 8 (7.4%) 7 (13.0%) 0.3
Features of heart failure 10 (6.0%) 6 (5.6%) 4 (7.4%) 0.7
No admission CXR 10 (6.0%) 7 (6.5%) 2 (3.7%) 0.7
Antimicrobial treatment
Piperacillinetazobactam 151 (57.2%) 107 (60.8%) 44 (50%) 0.1
Co-amoxiclav 33 (12.5%) 18 (10.2%) 15 (17.0%) 0.1
Metronidazole 22 (8.3%) 10 (5.7%) 12 (13.6%) 0.03
Vancomycin 19 (7.2%) 11 (6.3%) 8 (9.1%) 0.5
Ciprofloxacin 13 (4.9%) 7 (4.0%) 6 (6.8%) 0.4
Meropenem 13 (4.9%) 12 (6.8%) 1 (1.1%) 0.07
Ceftriaxone 4 (1.5%) 3 (1.7%) 1 (1.1%) 1.0
Amoxicillin 3 (1.1%) 3 (1.7%) 0 0.6
Gentamicin 2 (0.8%) 1 (0.6%) 1 (1.1%) 1.0
Clarithromycin 1 (0.4%) 1 (0.6%) 0 1.0
Linezolid 1 (0.4%) 1 (0.6%) 0 1.0
Minimum antimicrobial
duration, median days (IQR)
4 (3e5) 4 (3e6) 3.5 (2e5) 0.04
Outcomes
ICU admission 6 (3.6%) 6 (5.6%) 0 0.2
Intubation and ventilation 6 (3.6%) 6 (5.6%) 0 0.2
Death during admission 32 (19.3%) 22 (20.4%) 10 (18.5%) 0.8
HAP, hospital-acquired pneumonia; ICU, intensive care unit; CXR, chest X-ray; IQR, interquartile range.
a Comparing patients with radiologically confirmed HAP and patients with radiology inconsistent with HAP; chi-squared test or Fisher’s exact test
depending on number of subjects or two-sample Wilcoxon rank sum (WhitneyeMann) when comparing two medians.
b For emergency airway management, mechanical ventilation or general anaesthesia for surgery.
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Patients
This was a retrospective observational cohort study of
medical and surgical inpatients receiving intravenous antimi-
crobials for a clinical diagnosis of HAP at a tertiary care hospital
in Edinburgh, UK. Data were collected as part of a large pro-
spective audit of antimicrobial prescribing in all inpatients
within acute internal medicine and general surgery wards of
the Royal Infirmary of Edinburgh (RIE) over 13 months, between
April 2013 and April 2014. All patients treated with intravenous
antimicrobials for 48 h for any indication were identified and
reviewed by a consultant infectious disease physician and an
antimicrobial pharmacist. To be included in the current study,
a patient from this cohort had to be receiving intravenous
antimicrobials for a documented clinical diagnosis of HAP,
excluding VAP and CAP. Demographic data, medical history,
admission details (including death during admission), clinical
diagnosis (as deduced by the primary clinical team), micro-
biological sampling, and radiological investigations were
collected. Antimicrobial susceptibility testing was carried out
using the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) methodology.Definitions
The presence of signs and/or symptoms consistent with
respiratory tract infection was assumed based on the clin-
ical diagnosis of HAP made by the patient’s clinicians 48 h
after admission to hospital. To be classified as radiologi-
cally confirmed HAP in this study, chest X-ray evidence of a
new or progressive lung infiltrate was required (reported
by a radiologist), consistent with the 2005 ATS/IDSA
guidelines.1Analysis
Fisher’s exact test was used to compare categorical vari-
ables if one cell contained five or fewer subjects; chi-square
test was used if all cells contained more than five subjects.
The ShapiroeWilk W-test for non-normality was used to assess
the distribution of continuous data and the ManneWhitney
U-test was used for data not in a normal distribution. Data were
analysed using StatsDirect software version 2.8.0 (StatsDirect,
Altrincham, UK). P < 0.05 was considered statistically
significant.
Table III
Comparison of inflammatory markers
Inflammatory
marker
Radiologically
confirmed HAP
Radiology
inconsistent
with HAP
P-
valuea
(N ¼ 108) (N ¼ 54)
White cell count
(mean, 109/L)
14.7 11.0 0.0002
Neutrophil count
(mean, 109/L)
12.5 8.8 0.0001
C-reactive protein
(mean, mg/L)
150.6 88.1 0.0003
HAP, hospital-acquired pneumonia.
a The ShapiroeWilk test demonstrated that the data were not nor-
mally distributed, so the ManneWhitney U-test was used to compare
these continuous variables.
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Characteristics of patients treated for a clinical
diagnosis of HAP
Over the 13-month time-period, a total of 13,096 admissions
to eight wards in the RIE were reviewed. Overall 1745 of these
adult inpatients received 48 h of intravenous antimicrobials
(13.3%). Of these, 166 were treated for a clinical diagnosis of
HAP (9.51% of patients on intravenous antimicrobials) (Table I).
The cohort of patients was elderly, with a median age of 79.5
years. The majority of patients were aged75 years (62.7%) and
were male (59.6%); 75.3% of patients had been admitted to a
medical ward, and 24.7% to a surgical ward. Comorbidities, for
examplechronic obstructivepulmonarydisease, heart failureand
cardio-/cerebrovascular disease, were widespread in the cohort,
reflected in an inpatient mortality of 19.3% (Table II). Median
number of comorbidities was 2 with 28.3% of patients having>2.
Of the patients treated for HAP, 23.5% underwent a surgical
procedure under general anaesthetic prior to diagnosis and
treatment (Table II). A slightly higher percentage (27.1%) had
previously undergone endotracheal intubation during the
admission, reflecting some patients requiring intubation for
airway management or mechanical ventilation in the ICU, over
and above those intubated for general anaesthesia. Six patients
treated for a clinical diagnosis of HAP required ICU admission
and mechanical ventilation following clinical diagnosis of HAP.
The majority of patients had clear lung fields reported by a
radiologist on their admission chest X-ray. Nine percent of
patients had consolidation reported on admission, representing
an initial presentation with community-acquired pneumonia or
aspiration pneumonia before suspicion of and treatment for
HAP arising 48 h after admission.
In accordance with local guidelines for the treatment of
HAP, piperacillinetazobactam was the most frequently used
antimicrobial, prescribed to 57.2% of included patients
(Table II). Co-amoxiclav was the second most widely prescribed
antimicrobial, used in 12.5% of cases.
Microbiological sampling in patients treated for a
clinical diagnosis of HAP
In our study, blood cultures were drawn in the majority of
patients treated for HAP (75.9%). Sputum from 24.7% ofpatients was sent for culture. Six percent of patients had a
throat swab tested by quantitative polymerase chain reaction
(qPCR) for influenza A, influenza B, respiratory syncytial virus,
parainfluenza virus types 1e3, adenovirus, human corona-
viruses 229E, HKU1, NL63 and OC43, human metapneumovirus
rhinovirus, and Mycoplasma pneumoniae. Meticillin-resistant
Staphylococcus aureus (MRSA) screening was performed in
80.7% of patients during their admission. Following initiation of
treatment for suspected HAP, 4.2% of patients had a positive
C. difficile toxin assay result and an additional 4.2% had an
equivocal result (C. difficile screening test positive but
C. difficile toxin not detected) during their hospital admission
following treatment for HAP.Radiologically confirmed diagnosis of HAP
Of all 166 patients treated for a clinical diagnosis of HAP,
65.1% had radiological evidence of a new or progressive lung
infiltrate at the time of commencement of HAP treatment.
Assuming the presence of consistent clinical signs and/or
symptoms in addition, based on the clinical diagnosis of HAP,
these patients are considered to have met diagnostic criteria
for HAP according to the 2005 ATS/IDSA guidelines.1 In 32.5%,
chest imaging found no evidence of a new or progressive infil-
trate. No chest imaging was performed for four patients, and
these patients were excluded from the following analyses.
Radiologically confirmed HAP appeared to represent a
distinct clinical phenotype, with significantly higher levels of
inflammatory markers (white cell count, neutrophils, and C-
reactive protein; P < 0.05 for all) in these patients (Table III).
Patients with radiologically confirmed HAP were more likely to
have a white cell count greater than the upper limit of the local
reference range [odds ratio (OR): 3.23; 95% confidence interval
(CI): 1.57e6.83; P ¼ 0.0007]. Leucopenia was only observed in
one patient from each group. When the total duration of
intravenous antimicrobial therapy was considered, patients
with radiologically confirmed HAP had a longer median mini-
mum duration of treatment (3.5 days vs 4 days; P ¼ 0.04;
Table II) further suggesting that the two groups were clinically
different.
There was no significant difference in the use of piper-
acillinetazobactam, co-amoxiclav, vancomycin, ciprofloxacin
or meropenem between patients with and without radiological
confirmation of HAP. The mortality rate during admission for
patients with radiologically confirmed HAP was 20.4%, with
5.6% of patients requiring admission to the ICU and mechanical
ventilation following HAP diagnosis. In the group without
radiological confirmation, no patients went on to require ICU
admission and the mortality rate during admission was 18.5%
(P ¼ 0.8).Demographics associated with radiologically
confirmed HAP
Patient characteristics and admission details were
compared between patients treated for HAP with and without
radiological confirmation of a new/progressive infiltrate
(Tables I and II). Being admitted to a surgical ward (OR: 2.52,
95% CI: 1.03e6.87; P ¼ 0.04), undergoing surgery (requiring
general anaesthesia and intubation) (3.49; 1.31e10.98;
P ¼ 0.006) or endotracheal intubation for any indication (2.85;
Table IV
Microbiology results in patients with radiologically confirmed
HAP
Sample No.
Sputum culture (N ¼ 35)
No growth 5
Commensals 5
Yeasts 6
Coliforms 4
Escherichia coli 5
Pseudomonas aeruginosa 4
Staphylococcus aureus (MSSA) 5
Staphylococcus aureus (MRSA) 1
Enterobacter cloacae 1
Klebsiella oxytoca 1
Aspergillus fumigatusa 1
Blood culture (N ¼ 85)b
No growth 81
Klebsiella pneumoniae 1
Staphylococcus aureus (MRSA) 1
Proteus mirabilis 1
Streptococcus pneumoniae 1
MRSA screen (N ¼ 90)
Positive 5
qPCR for respiratory pathogensc (N ¼ 6)
Any positive result 0
HAP, hospital-acquired pneumonia; MRSA, meticillin-resistant
S. aureus; MSSA, meticillin-susceptible S. aureus.
a Single isolate, likely contaminant.
b All patients with positive blood cultures at time of HAP diag-
nosis had negative blood cultures earlier in admission.
c Influenza A, influenza B, respiratory syncytial virus, para-
influenza virus types 1e3, adenovirus, human coronaviruses 229E,
HKU1, NL63 and OC43, human metapneumovirus, rhinovirus, and
Mycoplasma pneumoniae.
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confirmed HAP. In surgical patients, there was no difference
between emergency/elective admissions. Patients from both
groups had a median of two medical comorbidities, and aside
from CKD no comorbidity was associated with radiologically
confirmed HAP.
Microbiology of radiologically confirmed HAP
Rates of microbiological sampling in patients with radio-
logically confirmed HAP were similar to the overall population
of patients treated for clinical suspicion of HAP. A bacterial
pathogen was identified from 17 of 35 sputum samples from
patients with radiologically confirmed HAP (48.6%; Table IV).
The majority of bacterial species identified in sputum samples
were Gram-negative bacilli (N ¼ 11) and S. aureus (N ¼ 6).
Sputum samples were obtained from six patients without
radiologically confirmed HAP and none of these yielded growth
of a bacterial pathogen.
Blood cultures were drawn in 78.7% of patients with radio-
logically confirmed HAP and bacteraemia was infrequent,
occurring in only four patients (sputum cultures were not ob-
tained from any of the patients with bacteraemia). Gram-
negative bacteria were responsible for two of these blood-
stream infections, and MRSA and S. pneumoniae accounted forone each. The patient with S. pneumoniae bacteraemia asso-
ciated with HAP had clear lung fields on admission chest X-ray.
A throat swab for qPCR testing for respiratory pathogens was
obtained from 5.6% of patients and was negative in all cases.
MRSA was found in only five of 90 MRSA screens (taken any time
during admission) and was identified from one sputum sample
and one blood culture (from different patients). Both of these
patients had a positive MRSA screen.
An antibiogram of the antimicrobial susceptibilities of bac-
teria isolated from sputum samples is shown in Supplementary
Table I. Overall, Gram-negative bacteria tended to be resistant
to amoxicillin and co-amoxiclav, but susceptible to ciproflox-
acin, gentamicin, piperacillinetazobactam, and meropenem.
Five out of six S. aureus isolates were susceptible to fluclox-
acillin and all six were susceptible to doxycycline (including the
one MRSA isolate). The MRSA sputum isolate was susceptible to
vancomycin.Discussion
We have retrospectively evaluated a cohort of 166 medical
and surgical inpatients treated for a clinical diagnosis of HAP.
Applying the 2005 ATS/IDSA HAP guidelines to these patients,
we identified that only 65.1% of patients had radiologically
confirmed HAP; therefore it appears that in ward-level hospital
practice at our institution ‘HAP’ is an over-used diagnosis that
may be inaccurate in more than one-third of cases. Surgical
ward admission, undergoing surgery with general anaesthesia,
or endotracheal intubation for any indication were associated
with radiologically confirmed HAP.
The 2005 ATS/IDSA guidelines describe intubation and me-
chanical ventilation as a risk factor for developing nosocomial
pneumonia, but the literature cited to support this statement
describes VAP, i.e. the development of pneumonia in patients
during mechanical ventilation.1 Hypothesis-generating univar-
iate analysis on our data suggests that intubation and ventila-
tion, especially when associated with surgery, may be a
continuing risk factor for pneumonia even following extubation
and is therefore a relevant factor when assessing non-
intubated patients with new respiratory signs and symptoms
in hospital. The pathogenesis of HAP may therefore often be
related to microaspiration of oropharyngeal contents around
the cuff of an endotracheal (ET) tube in paralysed intubated
patients during surgery, without necessarily a prolonged period
of mechanical ventilation such as during critical illness (i.e.
VAP). In a systematic literature review of airway management
strategies to reduce the incidence of VAP in critically ill
ventilated patients in the ICU, interventions including contin-
uous aspiration of subglottic secretions using a special ET tube
(vs standard ET tubes) and the use of heat and moisture ex-
changers have been shown to lower VAP rates.8 In a separate
study, persistent ET tube cuff pressure of <20 cmH2O was also
associated with risk of VAP.9 Such interventions could also be
evaluated in intubated patients undergoing surgery. Similarly,
in critically ill ventilated patients, oral hygiene with chlor-
hexidine mouthwash has been shown to reduce rates of VAP,
and has been included as a component of a successfully eval-
uated ‘VAP care bundle’.7,10 Chlorhexidine mouthwash would
be an inexpensive measure for use in the immediate pre- and
postoperative period for surgical patients. Oral care (chlor-
hexidine mouthwash or mechanical cleaning) was shown to be
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analysis incorporating non-ventilated hospital inpatients and
nursing home residents (though there was a high risk of bias in
included studies).11 Other postoperative factors likely to be
important in development of HAP include being bed-bound,
having reduced chest wall movement (and therefore reduced
clearance of secretions) due to pain or being drowsy secondary
to opiate analgesics.
In approximately one-third of patients treated for suspected
HAP in this study, a chest X-ray or computed tomography (CT)
excluded a pneumonic infiltrate, therefore an alternative
diagnosis may have been missed. A phenotype has been
described in ventilated ICU patients with respiratory signs but
no infiltrate on chest imaging, labelled nosocomial tracheo-
bronchitis.12 This has been associated with longer ICU admis-
sion and ventilation times but prospective data describing the
necessity for antimicrobials are lacking.12 Further study of this
phenotype in non-intubated patients may be valuable and it
may account for some of the cases in this study without
radiological changes consistent with HAP. Non-infective alter-
natives include atelectasis, pulmonary embolism, and under-
lying lung disease, such as chronic obstructive pulmonary
disease (present in 27.1% of patients treated for HAP in this
study) and asthma. Unwell patients labelled as ‘HAP’ may have
a subdiaphragmatic cause of sepsis resulting in the clinical
findings. Given the demonstrated difficulty in reaching a reli-
able clinical diagnosis of HAP, microbiological testing to
confirm an infective aetiology becomes even more important,
but a sputum sample was obtained from only 24.7% of patients
treated for HAP. This low rate may reflect the difficulty in
obtaining a suitable deep specimen from non-intubated pa-
tients with a degree of respiratory distress or weakness. In such
patients biomarkers of pulmonary infection would be helpful in
establishing the likelihood of an infective aetiology and justi-
fying the use of empirical antimicrobials prior to culture
results.
In comparison to community-acquired pneumonia, where
the culture-positive rate of sputum samples at our institution
has been reported as 30%, a bacterial pathogen was identified
from 17 of 35 (48.6%) samples from patients with radiologically
confirmed HAP and therefore has greater potential to influence
management.13 In our study, Gram-negative bacilli (11/17) and
S. aureus (6/17) were the identified pathogens, with no
frequently occurring CAP pathogens isolated. In the remainder
of cases where a sputum sample was obtained, the result was
‘no growth’, ‘respiratory commensals’ or ‘yeasts’. Antimicro-
bial resistance was significant, with most Gram-negative iso-
lates displaying resistance to amoxicillin and co-amoxiclav, but
susceptibility to piperacillinetazobactam. However, the over-
all number of sputum cultures obtained from patients was low,
reducing the utility of these data in describing themicrobiology
of HAP. In addition, we recognize the potential for contami-
nation of sputum samples with oropharyngeal colonizers. This
is an important issue, especially considering the prescription of
broad-spectrum antimicrobials to cover the susceptibility
pattern of these pathogens, but pragmatically one would aim
to cover these species if they were identified in a sputum
sample from a patient with HAP. As discussed above, the
inability to routinely obtain deep respiratory tract specimens
(e.g. BAL) from non-intubated patients hinders microbiological
diagnosis in HAP. The largest report on the microbiology of HAP
comes from a retrospective cohort study of a US inpatientdatabase of patients with culture-positive pneumonia,
including 835 patients with HAP.14 Here, S. aureus accounted
for 47.1% of cases, Pseudomonas spp. 18.4%, Klebsiella spp.
7.1%, Haemophilus spp. 5.6%, E. coli 4.7%, Enterobacter spp.
4.3%, and Acinetobacter spp. 2.0%. Overall, Gram-negative
pathogens were isolated from 45.8% of HAP cases. A compli-
cating factor in conventional culture-based testing of samples
from patients with suspected HAP is the fact they will most
likely already have received antimicrobials prior to sampling,
impairing sensitivity of pathogen detection using culture-based
techniques. A qPCR test for detection and quantification of
eight key bacterial causes of pneumonia (including S. aureus,
E. coli and P. aeruginosa) from sputum samples has recently
been described and could represent a useful tool for the
investigation of suspected HAP.15
Only six (5.6%) patients with HAP had throat swabs obtained
for qPCR respiratory virus and M. pneumoniae testing and in all
cases these were negative. Nosocomial influenza can account
for a significant proportion of influenza cases (17.3% in a Ca-
nadian surveillance programme).16 Using admission to critical
care wards as a marker, the 2013/14 influenza season in Scot-
land was similar to the preceding year with no significant in-
crease in cases.17 However, the lack of consistent testing for
influenza virus in patients with HAP precludes any conclusions
about the incidence of nosocomial influenza causing HAP dur-
ing the study period, or the utility of respiratory virus/myco-
plasma testing in the work-up of suspected HAP.
A limitation of this study is that radiological confirmation of
HAP is primarily derived from the results of chest X-rays (only
10 of the 166 patients underwent CT) which may lead to under-
detection of pulmonary infiltrates compared to CT.18e20 In a
study of 3423 patients presenting to the emergency depart-
ment with respiratory symptoms who underwent both chest X-
ray and CT, it has been demonstrated that X-ray has poor
sensitivity in detecting pulmonary infiltrates in comparison to
CT (sensitivity 43.5%).20 The timing of CT scan was not specified
in this study, therefore a confounding factor may be that a
possible delay between X-ray and CT allows development of a
detectable infiltrate. In cases where HAP is suspected clinically
but the chest X-ray does not show a new/progressive lung
infiltrate, there may be a role for CT scanning. In addition,
there is emerging evidence for the role of lung ultrasound for
the detection of pulmonary infiltrates in CAP, with some data
suggesting superiority over chest X-ray when compared to CTas
a gold standard.21,22 A further limitation lies in the casee
control analysis performed, which should be repeated in the
future with a control cohort of hospital inpatients with no
clinical suspicion of HAP. Furthermore, this study only identi-
fied patients receiving intravenous antimicrobials, thereby
selecting for patients perceived to have more severe illness.
When cases were identified during the antimicrobial pre-
scribing audit, a recommendation was made to the parent team
regarding further antimicrobial management. Whereas this
occurred after the clinical diagnosis of HAP had been made by
the patient’s team and would have had no influence on this, it
may have altered subsequent management. This could there-
fore confound the mortality data presented here, although no
significant difference was observed between patients with and
without radiologically confirmed HAP.
This study has described the features of radiologically
confirmed HAP in a cohort of UK inpatients. Potential risk
factors have been identified through a hypothesis-generating
C.D. Russell et al. / Journal of Hospital Infection 92 (2016) 273e279 279caseecontrol analysis using patients treated for suspicion of
HAP but without consistent radiology. Previous surgery and/or
endotracheal intubation were found to be associated with
radiologically confirmed HAP. Significantly, the clinical diag-
nosis of HAP may have been inaccurate in more than one-third
of cases, where there were no consistent changes on chest
imaging. We have also highlighted a lack of microbiological
sampling in patients receiving broad-spectrum antimicrobials
for a clinical diagnosis of HAP. Directions for further work on
HAP are highlighted in Supplementary Table II. Improved ac-
curacy of HAP diagnosis is essential, since around one-third of
patients in our cohort were exposed to broad-spectrum anti-
microbials potentially unnecessarily and may have had an
alternative diagnosis requiring different investigation and
management.
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